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Abstract. – OBJECTIVE: Alzheimer’s disease 
(AD) is a leading cause of years lived with dis-
ability in older age, and several cerebrospinal 
fluid (CSF) markers have been proposed in indi-
vidual meta-analyses to be associated with AD 
but field-wide evaluation and scrutiny of the lit-
erature is not available. 
MATERIALS AND METHODS: We performed an 
umbrella review for the reported associations be-
tween CSF biomarkers and AD. Data from available 
meta-analyses were reanalyzed using both random 
and fixed effects models. We also estimated be-
tween-study heterogeneity, small-study effects, ex-
cess significance, and prediction interval. 
RESULTS: A total of 38 meta-analyses on CSF 
markers from 11 eligible articles were identified 
and reanalyzed. In 14 (36%) of the meta-analy-
ses, the summary estimate and the results of the 
largest study showed non-concordant results in 
terms of statistical significance. Large heteroge-
neity (I2≥75%) was observed in 73% and small-
study effects under Egger’s test were shown in 
28% of CSF biomarkers. 
CONCLUSIONS: Our results suggest that there 
is an excess of statistically significant results 
and significant biases in the literature of CSF bio-
markers for AD. Therefore, the results of CSF bio-
markers should be interpreted with caution.
Key Words:
Alzheimer’s disease, CSF biomarkers, Meta-analysis, 
Umbrella review, Excess significance.
Introduction
Alzheimer’s disease (AD) is known as the lead-
ing cause of dementia, featuring a gradual cognitive 
decline accompanied by functional deterioration or 
behavioral changes1. It has also been one of the most 
challenging conditions to address from a medical 
and public health perspective2, due to a high per-
centage of undiagnosed and untreated patients, in 
addition to the absence of effective treatments3.
Though AD can be diagnosed after pathologic 
examination, directly sampling brain tissue is not 
a routinely available clinical method4. AD can al-
so be diagnosed according to generally accepted 
diagnostic symptomatic criteria; however, some 
symptoms are obscure and occasionally overlap 
with other neurologic disorders, making accurate 
diagnosis challenging5. 
Over the past several decades, in vivo biomark-
ers have received attention for their potential to 
demonstrate underlying pathologic characteris-
tics, as well as disease status or progression6. 
Considerable evidence has already shown 
that deposition of the aberrantly folded tau and 
amyloid beta proteins in neurofibrillary tangles 
and amyloid plaques are closely associated with 
pathologic changes of the patient’s brain2. Major 
neuropathological findings of AD, amyloid- and 
tau-related lesions, and neuronal dysfunction (in-
cluding pathologic synaptic conditions), can be 
identified even before the manifestation of clini-
cal signs, with the help of indirect methods such 
as the identification of the concentration variance 
of either tau or amyloid proteins in cerebrospinal 
fluids (CSF)5,6.
To date, some well-established biomarkers of 
AD from CSF include total tau (T-tau), phosphor-
ylated tau (P-tau), and amyloid-β-42 (Aβ42)7,8. 
Multiple individual meta-analyses focusing on 
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the effectiveness of several biomarkers have al-
ready been published9-12. Additionally, there have 
been several systematic reviews that described 
the biases of reported evidence in biomarkers for 
other neurologic and mental disorders13,14. How-
ever, there has been no comprehensive evaluation 
of various biases across the reports of studies 
of CSF biomarkers for AD. Therefore, we per-
formed an umbrella review and a systematic re-
view of meta-analyses which the highest levels of 
evidence15,16 for the reported associations between 
CSF biomarkers and AD. 
Materials and Methods
Search Strategy
This umbrella review was followed the Pre-
ferred Reporting Items for Systematic Reviews 
and Met Analyses (PRISMA) guidelines (Sup-
plementary Table I). To extract meta-analyses 
of AD addressing associations between specific 
biomarkers and AD, we searched PubMed records 
that were published up to January 15, 2020. Three 
of the authors (DYJ, ELP, JL) used the search 
terms (Alzheimer* All Fields or dementia* All 
Fields or dementing* All Fields) AND (meta All 
Fields or level All Fields). Article titles, abstracts, 
and full texts were used to screen for eligibility. 
We did not have any language restrictions while 
selecting the articles. Any discrepancies were dis-
cussed with the fourth investigator (JIS) and re-
solved by consensus of all four authors.
Our initial search yielded about 4,030 arti-
cles. Among those, 2,003 articles were left after 
we ruled out overlapping studies, review articles, 
studies related to polymorphism, and articles not 
based on meta-analyses. In addition, articles that 
described neurodegenerative disorders other than 
AD were excluded. Also, we excluded studies that 
examined genetic factors or peripheral biomarker 
levels, or studies that did not focus on CSF. We ul-
timately identified 11 eligible articles that satisfied 
the conditions for this review (Figure 1). 
Data Extraction
Three investigators (DYJ, ELP, JL) recorded 
the first author, journal title, and publication year 
from individual meta-analyses of eligible articles. 
Additionally, numbers of patients, controls, and 
studies were also recorded. We extracted the ef-
fect sizes with corresponding confidence intervals 
(CIs) and metric types. We tried to adopt either the 
effect size estimates or raw data, such as the mean, 
standard deviation (SD), median/interquartile, or 
median/range of original studies, if such factors 
were specified in the articles. However, if there 
were no raw data, we extracted the data from the 
individual original studies. If the data were rep-
resented as median/interquartile range, the mean 
and standard deviation were estimated by the 
following formula: (1) mean = (q1+median +q3)/3 
and (2) SD = (q3-q1)/1.35, where q1 and q3 are the 
25th and 75th percentiles17. In addition, median/
range may be approximately converted to mean ± 
SD according to the following formula: (1) mean 
= (a+2*median+b)/4 and (2) SD2 = {(a-2*median 
+b)2/4+(b-a)2}/12, where a and b are the minimum 
and maximum values18.
Statistical Analysis
For each meta-analysis, the summary estimate 
and its 95% CI with both random and fixed mod-
els19,20 were calculated by the same metric used by 
the author, as well as standard mean difference 
(SMD), and weighted mean difference (WMD). 
Figure 1. Flow chart of literature search.
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Random effects model was favored in the presence 
of within-study or between-study moderators, as 
it presumes diverse underlying uncertainties com-
pared to fixed effects model which assumes that 
all component studies are estimated by the same 
effect size21. We additionally calculated Hedge’s g 
by converting effect sizes from SMD to identify 
whether there were significant differences in sta-
tistical outcomes between those methods.
The heterogeneity across studies was estimated 
by the I2 index, which evaluates the impact of in-
consistency22. It is the ratio of between-study vari-
ance ranges to the sum of between-study and with-
in-study variances23. It ranges from 0% to 100%; 
and <50%, 50~75%, and >= 75% respectively 
demonstrate small, moderate, and large hetero-
geneity22. Publication bias was determined by the 
Egger’s test for asymmetry24. It is used to confirm 
the presence of small-study effects, which account 
for the tendency of small-sized studies to have 
larger effect sizes than those of larger studies25.
Excess significance (ES) test was performed to 
verify an excess number of positive studies com-
pared to the expected number by using a χ2 test26-28. 
A = (O – E) 2/E + (O – E) 2/(n – E) 
The observed number of positive studies is de-
noted as O and n refers to the total number of stud-
ies included in each meta-analysis. Expected num-
ber of positive studies E was obtained by the sum 
of the power for individual component study29. 
The power of each study was estimated in terms 
of a non-central t distribution30, using G*Power 
for Windows, version 3.1.9.2. We assumed that 
the power of each study could be replaced by the 
power of the largest study (the study with smallest 
variance)29. ES was claimed when p-value was less 
than 0.126 with the observed number of statistically 
significant studies larger than the expected num-
ber of statistically significant studies. 95% predic-
tion interval (PI) was also calculated, which could 
be used to describe the degree of between-study 
heterogeneity in addition to predicting the un-
certainty of the effect that may arise in a future 
study31-33. We also examined whether the largest 
study of each meta-analysis had a concordant 
result in terms of statistical significance with the 
summary results of the meta-analysis.
To compare the variables between groups as 
with ES and without ES, groups as with and with-
out having concordance with the largest study 
from the 38 meta-analyses, two-tailed independent 
t test and χ2 tests were used.
Statistical analysis was performed using Com-
prehensive Meta-Analysis software for Windows 
8. Statistical power was estimated by G*Power 
for Windows, Version 3.1.9.2. The SPSS statistical 
package (version 23.0, IBM Corp., Armonk, NY, 
USA) was used to perform independent t test and 
χ2 tests.
Results
We identified 11 eligible articles correspond-
ing to 38 meta-analyses of CSF biomarkers used 
to detect AD, which we reanalyzed. Overall, we 
included 624 studies with 66,198 cases assessing 
CSF biomarkers in AD. The average number of 
individual studies in each meta-analysis was 16, 
and the average sample size was 1,742. Of the 
38 eligible CSF-related meta-analyses, 17 (44%) 
were based on more than 500 cases, and 9 (23%) 
were based on more than 1,000 cases. 
Overall, 19 (51%) studies were statistically 
significant (p<0.05) under random effects model, 
and 10 (26%) were significant at a p-value less 
than 0.001 (Table I), which were meta-analyses 
of FA, T-tau, P-tau, A β42, NSE, 24-OHC, neuro-
granin, NFL, folate, and vitamin C. Compared to 
random effects model, meta-analyses under fixed 
effects model yielded less conservative results, as 
31 (81%) meta-analyses were statistically signif-
icant with p-values less than 0.05 and 24 (63%) 
had p-value less than 0.001. There were 22 (57%) 
studies with statistically significant (p<0.05) un-
der largest study effects, and 16 (42%) were sig-
nificant at a p-value less than 0.001. 
Five (13%) meta-analyses had small hetero-
geneity (I2<50%), which were meta-analyses of 
Al, MCP-1, SAP, folate, vitamin B12, vitamin C, 
and vitamin E, while 5 (13%) meta-analyses had 
moderate heterogeneity (50% ≤I2 <75%), and 28 
(73%) had large heterogeneity (I2≥75%). Two me-
ta-analysis, studying folate and vitamin C, had a 
95% PI excluding null. 11 (28%) of the meta-anal-
yses were found to have small-study effects un-
der Egger’s test. Additionally, 13 meta-analyses 
(34%) were confirmed to have ES. In 14 (36%) 
of the meta-analyses, the summary estimate and 
the results of the largest study showed non-con-
cordant results in terms of statistical significance 
(Table II). 
Correlations among variables from the 38 me-
ta-analyses between CSF biomarkers, patients 
with AD and controls are presented in Table III. 
The fixed effects size and largest study effects 
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size were correlated with random effects size 
significantly. The associations between largest 
study effect size and fixed effect size were al-
so significant. Egger p-value and I2(%) were 
not significantly correlated with other variables. 
When comparing the variables between the me-
ta-analysis group with ES and the meta-anal-
yses group without ES, the number of AD 
patients, only I2(%) was significantly higher in 
the meta-analysis group with ES (Table IV). 
Table I. Characteristics and quantitative reanalysis of the 38 meta-analyses concerning the CSF biomarkers between AD and 
controls.
  No. of Cases/  Random effects* p-value  p-value
 Biomarker studies controls Effect metrics (95% CI) (Random) Fixed effects† (Fixed)
P-tau  88 7210/5240 SMD 1.76 (1.51 to 2.01) < 0.001 1.19 (1.15 to 1.24) < 0.001
T-tau 154 11040/7343 SMD 2.02 (1.84 to 2.21) < 0.001 1.35 (1.31 to 1.39) < 0.001
Aβ42 131 9568/6818 SMD -2.36 (-2.6 to -2.11) < 0.001 -1.59 (-1.63 to -1.55) < 0.001
24-OHC  12 713/581 SMD 1.26 (0.65 to 1.86) <0.001 0.38 (0.26 to 0.5) < 0.001
FA   4 150/145 SMD -0.86 (-1.29 to -0.44) < 0.001 -0.76 (-1.01 to -0.52) < 0.001
HFABP   3 231/247 SMD 2.73 (0.39 to 5.06) 0.022 1.26 (1.04 to 1.48) < 0.001
MCP-1   3 59/59 SMD 0.89 (0.35 to 1.42) 0.001 0.93 (0.54 to 1.31) < 0.001
NSE   6 234/140 SMD 0.62 (0.27 to 0.96) < 0.001 0.65 (0.43 to 0.87) < 0.001
27-OHC   6 269/294 SMD 1.95 (0.7 to 3.19) 0.002 0.56 (0.38 to 0.75) < 0.001
TGF-β   5 113/114 WMD 7.81 (2.27 to 13.35) 0.006 0.32 (-0.04 to 0.69) 0.083
VLP-1   4 252/486 SMD 3.1 (0.53 to 5.68) 0.018 1.42 (1.23 to 1.62) < 0.001
YKL-40   5 274/504 SMD 2 (0.42 to 3.57) 0.013 1.69 (1.5 to 1.89) < 0.001
Aβ40  21 959/759 SMD -0.23 (-0.41 to -0.05) 0.011 -0.22 (-0.32 to -0.11) < 0.001
Al   4 47/77 SMD 0.48 (0.02 to 0.93) 0.04 0.46 (0.08 to 0.83) 0.017
Cu   5 116/129 SMD 0.39 (-0.55 to 1.34) 0.418 0.36 (0.08 to 0.63) 0.011
Hcy   5 239/226 SMD 0 (-0.27 to 0.28) 0.978 -0.03 (-0.22 to 0.16) 0.76
IL-1β   5 99/80 SMD -0.2 (-1.05 to 0.65) 0.639 -0.09 (-0.4 to 0.22) 0.563
IL-6   9 208/160 SMD -0.22 (-0.9 to 0.46) 0.523 0.1 (-0.12 to 0.32) 0.365
TNF-α   4 121/78 SMD -0.26 (-4.81 to 4.29) 0.912 0.52 (0.09 to 0.95) 0.018
Aβ38   5 203/145 SMD 0.07 (-0.41 to 0.55) 0.771 -0.03 (-0.25 to 0.19) 0.798
Albumin ratio  20 854/514 SMD 0.28 (-0.04 to 0.61) 0.086 0.28 (0.16 to 0.39) < 0.001
ApoE  24 1064/1338 WMD -0.3 (-0.69 to 0.09) 0.135 0.08 (-0.03 to 0.19) 0.165
Cholesterol  16 959/694 SMD -0.23 (-0.66 to 0.19) 0.286 -0.46 (-0.57 to -0.36) < 0.001
C3   4 299/522 Cohen’s D 0.45 (0.18 to 0.73) 0.001 0.44 (0.29 to 0.59) < 0.001
Clusterin   9 625/577 Cohen’s D 7.09 (-4.02 to 18.2) 0.211 3.73 (3.61 to 3.84) < 0.001
C1q   4 160/127 Cohen’s D 0.28 (-0.41 to 0.97) 0.425 0.48 (0.24 to 0.72) < 0.001
CRP   4 421/450 Cohen’s D 0.27 (-0.26 to 0.8) 0.318 0.11 (-0.03 to 0.26) 0.124
SAP   5 397/394 Cohen’s D 0.12 (-0.12 to 0.36) 0.333 0.1 (-0.06 to 0.26) 0.235
Factor H   3 233/394 Cohen’s D 0.41 (-0.06 to 0.88) 0.09 0.33 (0.17 to 0.49) < 0.001
sAPPα  15 575/383 WMD -9.62 (-40.11 to 20.88) 0.537 23.96 (18.45 to 29.48) < 0.001
sAPPβ  13 581/415 WMD 37.05 (-9.96 to 84.07) 0.122 43.96 (36.03 to 51.9) < 0.001
Neurogranin  10 908/660 Cohen’s D 268.25 (143.49 to 393.02) < 0.001 138.04 (131.09 to 144.98) < 0.001
DHEA   4 84/78 Cohen’s D 2.16 (-1.88 to 6.21) 0.294 1.11 (0.65 to 1.57) < 0.001
NFL  24 1071/1219 Cohen’s D 1.57 (1.12 to 2.01) < 0.001 1.3 (1.2 to 1.41) < 0.001
Folate   9 307/538 Cohen’s D -0.47 (-0.63 to -0.32) < 0.001 -0.47 (-0.63 to -0.32) < 0.001
Vitamin B12   4 92/208 Cohen’s D -0.42 (-0.79 to -0.04) 0.028 -0.4 (-0.75 to -0.06) 0.022
Vitamin C   5 102/79 Cohen’s D -0.83 (-1.16 to -0.5) < 0.001 -0.83 (-1.15 to -0.52) < 0.001
Vitamin E   5 127/100 Cohen’s D -0.51 (-1.1 to 0.08) 0.088 -0.41 (-0.68 to -0.14) 0.003
Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; Random effects, summary effect size (95% CI) using random 
effects model; Fixed effects, summary effect size (95% CI) using fixed effects model; Largest effect, effect size (95% CI) of the 
largest study in the meta-analysis; Egger, p-value from Egger’s regression asymmetry test for evaluation of publication bias; 
P, p-value; SMD, standard mean difference; WMD, weighted mean difference; PI, prediction interval; ES, excess significance; 
RoM, ratio of the mean; IL, interleukin; TGF, tumor growth factor; TNF, tumor necrosis factor; Al, aluminum; Hcy, homocysteine; 
FA, folic acid, Apo, apolipoprotein; T-tau, total tau protein; P-tau; phosphorylated tau protein; Aβ, amyloid beta, NSE, neuron 
specific enolase; VLP, visinin like protein; HFABP, heart-type fatty acid binding protein; YKL-40, chitinase-3-like protein 1; 
MCP, monocyte chemoattractant protein; OHC, hydroxycholesterol; C3, third component of complement; CRP, C-reactive 
protein; SAP, serum amyloid P component; FH, factor H; sAPPα, soluble amyloid precursor protein procurer α; sAPPβ, soluble 
amyloid precursor protein procurer β, DHEA, dehydroepiandrosterone; NFL, neurofilament light. *Summary random effects 
effect size (95% CI) of each meta-analysis.†Summary fixed effects effect size (95% CI) of each meta-analysis. ‡Effect size (95% 
CI) of the largest study in each meta-analysis. §p-value from the Egger regression asymmetry test for evaluation of publication 
bias.||I2 metric of inconsistency (95% confidence intervals of I2) and p-value of the Cochran Q test for evaluation of heterogeneity. 
¶Concordance between largest study estimate and random effects summary estimate.
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When comparing the variables between the me-
ta-analysis group with concordance with the 
largest study and the meta-analyses group with 
discordance with the largest study, there was no 
significant difference between groups (Table V). 
Causes for the statistical changes after reanaly-
sis are shown in Table VI.
Discussion
There is a pressing need to identify poten-
tial biomarkers for AD, and to the best of our 
knowledge, the current paper is the first sys-
tematic review to comprehensively evaluate the 
entire field of CSF biomarkers and AD. Specif-
ically, in this review, we reanalyzed the current 
meta-analyses on associations of CSF biomark-
er levels between AD patients and healthy con-
trols. We systemically appraised 38 biomarkers 
from CSF. To the best of our knowledge, this 
was the first attempt to synthesize evidence on 
CSF biomarkers of AD while evaluating biases 
within the literature. Several similar efforts 
have been reported in the field of neuropsy-
chiatric disorders34,35, which found substantial 
biases across multiple meta-analyses utilizing 
diverse statistical indices to interpret existing 
meta-analyses36.
More than half of the eligible meta-analyses 
had reported statistically significant associa-
tion. Twenty (53%) were significant accord-
ing to meta-analyses under a random effects 
model. However, for many of them, we found 
evidence of bias after reanalyzing and calcu-
lating additional statistical indices. Most of 
the associations had PIs including the null and 
were not aimed at a sufficiently large number of 
cases (over 1,000). 
Most of the meta-analyses had substantial 
heterogeneity, and the meta-analyses with low 
heterogeneity may have included a small num-
ber of studies or cases, and therefore should be 
interpreted with caution. Heterogeneity could 
be explained by the differences in individual 
characteristics of subjects within a group, such 
as age, gender, ethnicity, or severity of the dis-
ease. Still, a consensus on the diagnostic cri-
teria of dementia remains to be unestablished, 
which could contribute to the heterogeneity34. 
Other contributing factors could be the dif-
ference in methodology of the primary stud-
ies, such as sample preparation and detection 
methods.  
Only two biomarkers, FA and vitamin C, was 
supported by a meta-analysis in which PI ex-
cluded the null. It was estimated to have small 
heterogeneity. Conversely, most significant re-
sults, at a p-value less than 0.05 using random 
effects model, had a PI including the null. 
They also tended to have relatively substantial 
heterogeneity, which was to be expected given 
that the PI was used to describe between-study 
heterogeneity. A PI including the null sug-
gests a possible existence of uncertainty, which 
might be due to the confounding factors cited 
above as well as a number of unknown sources 
of biases.
ES was introduced to determine the existence 
of excessively observed significant results. One 
consequence of selective analysis reporting is 
ES27. For comparison with ES, the p-value for 
Egger’s test, which is a traditional indicator of 
publication bias37, was calculated to estimate 
small-study effects. In our analysis, the propor-
tion of biomarkers with ES was about 34% and 
the proportion of biomarkers with small-study 
effects was about 28%. Moreover, the number 
of biomarkers with ES was larger than the num-
ber of biomarkers with small-study effects.
Effect sizes under random and fixed models 
were highly correlated. It was assumed that 
all meta-analyses would have a common true 
effect size in a fixed model, while a random 
model would have variable effect sizes across 
studies38. Although they were significantly cor-
related, most of the overall results under ran-
dom models were conservative with a wider 
CI compared to those under fixed models, as 
we expected. Since the sources of variation 
in a random model were relevant to the be-
tween-study heterogeneity as well as the with-
in-study error, a random effects model might 
generally be more suitable in cases where 
individual studies were collected from the pub-
lished literature38. 
Commonly accepted CSF biomarkers for di-
agnosing AD are T-tau, P-tau, and Aβ4239. 
They have been reported to have relatively 
favorable diagnostic accuracy when used for 
verifying the prodromal phase of AD40,41. In 
our analysis, they were substantially significant 
at p-value less than 0.001 under random effects 
model; however, the meta-analyses had a high 
level of heterogeneity, small-study effects, and 
ES. Heterogeneity could be considered large, 
though a significant number of studies account-
ed for the majority. Meanwhile a large number 
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Table II. Characteristics and bias test of the 38 meta-analyses concerning the CSF biomarkers between AD and controls.
  No. of  Largest study effects‡ p-value  I2 (%)
 Biomarker studies Cases/controls (95% CI) (Largest) I2 (%) (p)|| PI Egger§ (p) ES Concordance¶ 
P-tau  88 7210/5240 0.64 (0.5 to 0.78) < 0.001  97 < 0.001 -0.57 to 4.09 < 0.001 No Cor
T-tau 154 11040/7343 1.13 (0.99 to 1.27) < 0.001  96 < 0.001 -0.19 to 4.23 < 0.001 No Cor
Aβ42 131 9568/6818 -1.53 (-1.68 to -1.38) < 0.001  97 < 0.001 -5.12 to 0.41 < 0.001 No Cor
24-OHC  12 713/581 -0.03 (-0.3 to 0.24) 0.836  96 < 0.001 -1.11 to 3.62 0.002 Yes Dis
FA   4 150/145 -0.57 (-0.96 to -0.18) 0.004  58 0.065 -2.52 to 0.8 0.009 No Cor
HFABP   3 231/247 0.75 (0.42 to 1.07) < 0.001  99 < 0.001 -27.37 to 32.82 0.013 No Cor
MCP-1   3 59/59 1.08 (0.49 to 1.68) < 0.001  47 0.15 -4.5 to 6.28 0.258 No Cor
NSE   6 234/140 0.79 (0.35 to 1.23) < 0.001  58 0.036 -0.41 to 1.65 0.45 No Cor
27-OHC   6 269/294 -0.12 (-0.4 to 0.16) 0.408  97 < 0.001 -2.6 to 6.5 0.017 Yes Dis
TGF-β   5 113/114 0.2 (-0.17 to 0.57) 0.293  93 < 0.001 -11.11 to 26.72 0.089 Yes Dis
VLP-1   4 252/486 0.79 (0.55 to 1.04) < 0.001  99 < 0.001 -9.47 to 15.68 0.241 No Cor
YKL-40  5 274/504 0.51 (0.19 to 0.83) 0.002  98 < 0.001 -4.23 to 8.22 0.536 No Cor
Aβ40  21 959/759 -0.26 (-0.6 to 0.09) 0.147  64 < 0.001 -0.95 to 0.48 0.48 No Dis
Al   4 47/77 0.28 (-0.25 to 0.81) 0.305  25 0.26 -0.94 to 1.89 0.844 No Dis
Cu   5 116/129 -0.24 (-0.78 to 0.3) 0.386  91 < 0.001 -3.21 to 3.99 0.832 Yes Cor
Hcy   5 239/226 -0.01 (-0.34 to 0.32) 0.958  48 0.1 -0.82 to 0.82 0.213 No Cor
IL-1β   5 99/80 0.64 (0.11 to 1.17) 0.017  86 < 0.001 -3.36 to 2.95 0.5 No Dis
IL-6   9 208/160 0.25 (-0.22 to 0.72) 0.299  89 < 0.001 -2.61 to 2.17 0.103 Yes Cor
TNF-α   4 121/78 0.36 (-0.17 to 0.88) 0.182  99 < 0.001 -22.33 to 21.82 0.97 No Cor
Aβ38   5 203/145 -0.54 (-0.93 to -0.16) 0.005  77 0.002 -1.63 to 1.77 0.135 No Dis
Albumin ratio  20 854/514 0.41 (0.08 to 0.74) 0.016  86 < 0.001 -1.18 to 1.75 0.939 No Dis
ApoE  24 1064/1338 1.3 (1.02 to 1.58) < 0.001  90 < 0.001 -2.13 to 1.53 0.053 No Dis
Cholesterol  16 959/694 -0.62 (-0.89 to -0.35) < 0.001  93 < 0.001 -2.07 to 1.6 0.108 No Dis
C3   4 299/522 0.43 (0.18 to 0.68) < 0.001  68 0.025 -0.7 to 1.6 0.772 No Cor
Clusterin   9 625/577 0.58 (0.42 to 0.74) < 0.001 100 < 0.001 -35.29 to 49.48 0.512 No Dis
C1q   4 160/127 0.61 (0.32 to 0.9) < 0.001  80 0.002 -2.77 to 3.33 0.534 No Dis
CRP   4 421/450 -0.07 (-0.31 to 0.17) 0.579  92 < 0.001 -2.23 to 2.77 0.096 No Cor
SAP   5 397/394 0.1 (-0.14 to 0.34) 0.422  44 0.129 -0.56 to 0.79 0.733 No Cor
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Abbreviations: AD, Alzheimer’s disease; CSF, cerebrospinal fluid; Random effects, summary effect size (95% CI) using random effects model; Fixed effects, summary effect 
size (95% CI) using fixed effects model; Largest effect, effect size (95% CI) of the largest study in the meta-analysis; Egger, p-value from Egger’s regression asymmetry test for 
evaluation of publication bias; P, p-value; SMD, standard mean difference; WMD, weighted mean difference; PI, prediction interval; ES, excess significance; RoM, ratio of the 
mean; IL, interleukin; TGF, tumor growth factor; TNF, tumor necrosis factor; Al, aluminum; Hcy, homocysteine; FA, folic acid, Apo, apolipoprotein; T-tau, total tau protein; P-tau; 
phosphorylated tau protein; Aβ, amyloid beta, NSE, neuron specific enolase; VLP, visinin like protein; HFABP, heart-type fatty acid binding protein; YKL-40, chitinase-3-like 
protein 1; MCP, monocyte chemoattractant protein; OHC, hydroxycholesterol; C3, third component of complement; CRP, C-reactive protein; SAP, serum amyloid P component; FH, 
factor H; sAPPα, soluble amyloid precursor protein procurer α; sAPPβ, soluble amyloid precursor protein procurer β, DHEA, dehydroepiandrosterone; NFL, neurofilament light.
*Summary random effects effect size (95% CI) of each meta-analysis. †Summary fixed effects effect size (95% CI) of each meta-analysis. ‡Effect size (95% CI) of the largest study 
in each meta-analysis. §p-value from the Egger regression asymmetry test for evaluation of publication bias. ||I2 metric of inconsistency (95% confidence intervals of I2) and p-value 
of the Cochran Q test for evaluation of heterogeneity. ¶Concordance between largest study estimate and random effects summary estimate.
Table II (Continued). Characteristics and bias test of the 38 meta-analyses concerning the CSF biomarkers between AD and controls.
  No. of  Largest study effects‡ p-value  I2 (%)
 Biomarker studies Cases/controls (95% CI) (Largest) I2 (%) (p)|| PI Egger§ (p) ES Concordance¶ 
Factor H   3 233/394 0.1 (-0.14 to 0.34) 0.422  88 < 0.001 -5.41 to 6.22 0.197 No Cor
sAPPα  15 575/383 4.18 (-4.15 to 12.51) 0.33  93 < 0.001 -116.08 to 96.85 0.198 No Cor
sAPPβ  13 581/415 9.25 (-4.79 to 23.3) 0.198  96 < 0.001 -139.14 to 213.25 0.964 No Cor
Neurogranin  10 908/660 79.25 (70.06 to 88.44) < 0.001 100 < 0.001 -209.76 to 746.27 0.217 No Cor
DHEA   4 84/78 1.19 (0.51 to 1.87) < 0.001  99 < 0.001 -17.53 to 21.86 0.538 No Dis
NFL  24 1071/1219 0.99 (0.7 to 1.28) < 0.001  94 < 0.001 -0.59 to 3.72 0.001 No Cor
Folate   9 307/538 -0.3 (-0.64 to 0.04) 0.083   0 0.475 -0.66 to -0.29 0.358 No Dis
Vitamin B12   4 92/208 -0.32 (-0.86 to 0.22) 0.248  11 0.339 -1.4 to 0.57 0.194 No Dis
Vitamin C   5 102/79 -1.19 (-1.8 to -0.57) <0.001   9 0.354 -1.48 to -0.19 0.547 No Cor
Vitamin E  5 127/100 -0.51 (-0.96 to -0.07) 0.024  76 0.002 -2.57 to 1.55 0.431 No Dis
AD, Alzheimer’s disease; (-): negative correlation coefficient. 
Table III. Correlations among variables from the 38 meta-analyses concerning the CSF biomarkers between AD and controls.
 Number of Number of Number Total number Random effects Fixed effects Largest study Egger
 studies AD patients of controls of participants effect size effect size  effect size p-value I2
Number of studies  0.995 0.990 0.994 -0.036(-) -0.043(-) -0.040(-) -0.149(-) 0.241(-)
Number of AD patients 0.995  0.995 0.999 -0.012(-) -0.026(-) -0.017(-) -0.145(-) 0.247(-)
Number of controls 0.990 0.995  0.998 -0.018(-) -0.035(-) -0.024(-) -0.181(-) 0.255(-)
Total number of participants 0.994 0.999 0.998  -0.014(-) -0.029(-) -0.020(-) -0.168(-) 0.250(-)
Random effects effect size -0.036(-) -0.012(-) -0.018(-) -0.014(-)  0.964 0.994 -0.083(-) 0.166(-)
Fixed effects effect size -0.043(-) -0.026(-) -0.035(-) -0.029(-) 0.964  0.974 -0.057(-) 0.197(-)
Largest study effect size -0.040(-) -0.017(-) -0.024(-) -0.020(-) 0.994 0.974  -0.096(-) 0.169(-)
Egger p-value -0.149(-) -0.145(-) -0.181(-) -0.168(-) -0.083(-) -0.057(-) -0.096(-)  0.027(-)
I2 (%) 0.241(-) 0.247(-) 0.255(-) 0.250(-) 0.166(-) 0.197(-) 0.169(-) 0.027(-) 
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of estimated effects within the meta-analysis 
can make in the same direction, differently as-
sessed magnitude of each effect may generate 
the heterogeneity.
Effect sizes of the largest studies were sig-
nificantly correlated with both random effect 
sizes and fixed effect sizes in the analysis. 
However, no significant correlation was found 
between  largest study effect size and egger 
p-value or I2 (%). If true effect sizes were as-
sumed to be equivalent to those of the largest 
studies, it could be asserted that random effect 
models generated more plausible results in this 
review, where between-study variances were 
significant. Furthermore, the analysis showed 
no significant difference of variables between 
meta-analysis group with ES and meta-anal-
ysis group without ES, except I2 (%). In ad-
dition, there was no significant difference in 
most variables between meta-analysis group 
with concordance with the largest study and 
meta-analysis group without concordance to 
Table IV. Comparison of variables between groups with or without ES from the 38 meta-analyses concerning the CSF 
biomarkers between AD and controls.
 Group I ith ES Group II without ES p-value
Number of studies 7.33 ± 2.73 18.14 ± 34.51 0.453
Number of AD patients 304.50 ± 228.19 1148.77 ± 2585.30 0.434
Number of controls 243.00 ± 177.39 898.89 ± 1775.27 0.376
Total number of participants 547.50 ± 396.38 2048.66 ± 4355.76 0.409
Random effects effect size 1.89 ± 2.99 9.03 ± 45.54 0.704
Fixed effects effect size 0.17 ± 0.40 6.23 ± 24.39 0.550
Largest study effect size 0.00 2.83 ± 13.37 0.611
Egger p-value 0.33 ± 0.51 0.34 ± 0.48 0.962
I2 (%) 93.20 ± 3.34 74.76 ± 29.41 0.001
ES, excess significance; CSF, cerebrospinal fluid; AD, Alzheimer’s disease.
Table V. Comparison of variables between groups with or without concordance with the largest study from the 38 meta-
analyses concerning the CSF biomarkers between AD and controls.
 Group I concordant Group II discordant 
 with the  without the 
 largest study largest study p-value
Number of studies 21.58 ± 41.15 9.47 ± 6.70 0.169
Number of AD patients 1453.83 ± 3081.63 420.12 ± 362.90 0.117
Number of controls 1105.25 ± 2109.69 378.12 ± 343.82 0.110
Total number of participants 2559.08 ± 5187.69 798.24 ± 687.54 0.113
Random effects effect size 12.83 ± 54.92 1.12 ± 2.52 0.387
Fixed effects effect size 8.88 ± 29.25 0.35 ± 0.99 0.167
Largest study effect size 4.04 ± 16.09 0.12 ± 0.69 0.323
Egger p-value 0.38 ± 0.49 0.29 ± 0.47 0.587
I2 (%) 78.00 ± 25.21 70.24 ± 33.67 0.403
CSF, cerebrospinal fluid; AD, Alzheimer’s disease; Genetic comparisons additionally extracted from GWAS catalog were also 
re-analyzed (Table III)27-31. All 18 of the re-analyzed genetic comparisons from four articles had a p-value < 0·05. Among the 
18 noteworthy comparisons, two genotype comparisons extracted from GWAS catalog were reported to be significant with a 
p-value < 5×10-8. Out of two genotype comparisons, only one (50%) was verified to be noteworthy (<0·2) using FPRP estimation, 
at a prior probability of 10-3 with a statistical power to detect an OR 1.2. In addition, two (100%) and one (50%) showed 
noteworthiness at prior probability of 10-3 and 10-6 with a statistical power to detect an OR 1·5. Under BFDP estimation, two 
(100%) and one (50%) were assessed to be noteworthy at prior probability of 10-3 and 10-6. On the other hand, all 16 of the re-
analyzed genetic comparisons extracted from GWAS catalog had a borderline statistical significance (p-value between 0·05 and 
5×10-8). Under RPRP estimation, six (37·5%) and three (18·7%) were assessed to be noteworthy at prior probability of 10-3 and 
10-6 with a statistical power to detect an OR of 1·2. Moreover, 14 (87·5%) were identified as noteworthy at a prior probability 
of 10-3 with a statistical power to detect an OR of 1·5. In terms of BFDP, 15 (93·7%) and one (6·2%) had noteworthy findings 
(<0·8) at a prior probability of 10-3 and 10-6. Consequently, 14 (87·5%) SNPs were found noteworthy using FPRP and BFDP.
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the largest study. Our results showed the het-
erogeneity in the meta-analysis of biomarkers 
of Alzheimer’s disease might be heavily due 
to both of the magnitude of the estimates and 
a direction of the estimates for the biomarkers. 
It is necessary to derive the result of umbrel-
la review considering variance and to avoid 
checking the level of study without sufficient 
consideration of these characteristics of hetero-
geneity and biases in meta-analysis.
Our review has several limitations. First, 
some meta-analyses could not be reanalyzed 
due to insufficient raw data. Also, five stud-
ies were excluded from ES analysis, due to 
unavailable raw data. Second, some of the 
meta-analyses were reanalyzed under different 
metrics, which may have produced discrep-
ancies in the summary results. Nevertheless, 
we attempted to reanalyze the meta-analyses 
regarding the associations between CSF bio-
markers and AD by using additional statistical 
indices to investigate their statistical validity. 
Although considerable portion of the existing 
meta-analyses have reported on the statistical 
significance of associations, we recommend in-
terpreting those results with caution, especially 
in cases with a high level of heterogeneity. 
Currently, there is no existing single significant 
method that can demonstrate the validity of the 
associations. However, we think using these 
bias tests can guide the interpretation of the 
results from meta-analyses.
Conclusions
We evaluated the meta-analyses available using 
CSF biomarkers in diagnosing Alzheimer’s Dis-
ease. Our study suggests that significant biases, 
coupled with substantial heterogeneity between me-
ta-analyses, necessitate that meta-analyses in diag-
nostic CSF biomarkers be interpreted with caution.
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Table VI. Causes for the statistical changes after reanalysis.
       Causes for changes
   Cases/  Cases/ Changes in the number of
  Studies controls Studies controls in analysis studies reanlalyzed
 Comparison (Author) (Author) (Reanalyzed) (Reanalyzed) results or results 
Albumin ratio  20 854/441  20 854/441 Yes Analyzed by the different metric
T-tau 151 11341/7086 142 11087/6848 No Insufficient raw data
P-tau  89 7498/5126  81 7261/4898 No Insufficient raw data
Aβ42 131 9949/6841 120 9595/6399 No Insufficient raw data
Aβ40  25 1079/784  21 959/669 No Insufficient raw data
Aβ38   8 251/195   5 203/145 No Insufficient raw data
sAPPα   9 572/415   7 408/180 No Insufficient raw data
sAPPβ  10 631/439   8 467/204 Yes Insufficient raw data, Analyzed 
      by the different Metric
NFL   9 245/292   7 195/237 No Insufficient raw data
NSE   7 258/160   6 234/140 No Insufficient raw data
VLP-1   4 252/486   4 252/486 No Insufficient raw data
HFABP   5 285/297   3 231/247 No Insufficient raw data
YKL-40   6 298/330   5 274/306 No Insufficient raw data
GFAP   2 59/39   1 35/19 Can’t be Insufficient raw data
     reanalyzed
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